

Carmen Alonso-Cotoner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4063301/publications.pdf>

Version: 2024-02-01

48
papers

2,757
citations

201385

27
h-index

243296

44
g-index

49
all docs

49
docs citations

49
times ranked

3539
citing authors

#	ARTICLE	IF	CITATIONS
1	Tratamiento angiográfico percutáneo de lesión vascular colónica en paciente anticoagulada. <i>Gastroenterología Y Hepatología</i> , 2022, 45, 282-283.	0.2	0
2	Severity of gastrointestinal bleeding is similar between patients receiving direct oral anticoagulants or vitamin K antagonists. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	2
3	Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations. <i>Cells</i> , 2022, 11, 2046.	1.8	4
4	The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults. <i>Advances in Therapy</i> , 2021, 38, 2054-2076.	1.3	8
5	Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?. <i>Biology</i> , 2021, 10, 340.	1.3	4
6	Present and Future Therapeutic Approaches to Barrier Dysfunction. <i>Frontiers in Nutrition</i> , 2021, 8, 718093.	1.6	21
7	Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2020, 10, 20706.	1.6	21
8	Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2020, 115, 2047-2059.	0.2	16
9	Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis. <i>Cells</i> , 2019, 8, 135.	1.8	115
10	Anemia microcítica secundaria a úlceras anastomóticas ileocelicas. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 111-112.	0.2	0
11	A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. <i>Advances in Therapy</i> , 2018, 35, 289-310.	1.3	152
12	Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction. <i>Scientific Reports</i> , 2018, 8, 2255.	1.6	18
13	Registro informatizado de la telangiectasia hemorrágica hereditaria (Registro RiHHTa) en España: objetivos, métodos y resultados preliminares. <i>Revista Clinica Espanola</i> , 2018, 218, 468-476.	0.2	11
14	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. <i>Gut</i> , 2017, 66, 1537.1-1538.	6.1	105
15	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 909-922.	1.9	81
16	Acute Stress Impacts Clock Genes and Barrier Integrity in the Intestinal Mucosa in Health. <i>Gastroenterology</i> , 2017, 152, S919.	0.6	0
17	Integrated Multi-Omic Analysis Reveals Female Predominance of Deregulated Mucosal Actin Depolymerization by Decreased Tesk1-Mediated CFL1-Phosphorylation in IBS-D. <i>Gastroenterology</i> , 2017, 152, S721.	0.6	0
18	Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. <i>United European Gastroenterology Journal</i> , 2017, 5, 887-897.	1.6	40

#	ARTICLE	IF	CITATIONS
19	Stress Induces Specific Gender-Related Molecular Alterations in Barrier Regulatory Genes in the Jejunal Mucosa of Healthy. <i>Gastroenterology</i> , 2017, 152, S720-S721.	0.6	0
20	Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 53-63.	1.4	47
21	Cognitive and hedonic responses to meal ingestion correlate with changes in circulating metabolites. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1806-1814.	1.6	27
22	Epidemiological and clinical profile of adult patients with <i>Blastocystis</i> sp. infection in Barcelona, Spain. <i>Parasites and Vectors</i> , 2016, 9, 548.	1.0	26
23	The joint power of sex and stress to modulate brain-gut microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016, 28, 463-486.	1.6	62
24	Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 033-050.	0.8	84
25	Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. <i>Gut</i> , 2015, 64, 1379-1388.	6.1	94
26	The intestinal barrier function and its involvement in digestive disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 686-96.	0.1	121
27	Intestinal Barrier Function and the Brain-Gut Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 73-113.	0.8	43
28	Circulatory Antigen Processing by Mucosal Dendritic Cells Controls CD8+ T Cell Activation. <i>Immunity</i> , 2013, 38, 153-165.	6.6	92
29	Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. <i>Gut</i> , 2013, 62, 1160-1168.	6.1	229
30	Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 232-234.	0.1	27
31	The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. <i>American Journal of Gastroenterology</i> , 2012, 107, 736-746.	0.2	169
32	Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 603-612.	0.9	35
33	Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. <i>Psychoneuroendocrinology</i> , 2012, 37, 65-77.	1.3	62
34	Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability. <i>Neurogastroenterology and Motility</i> , 2012, 24, 740.	1.6	55
35	Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2416-2426.	0.9	15
36	Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1166-1175.	2.0	88

#	ARTICLE	IF	CITATIONS
37	Editorial: A Closer Look at Mucosal Inflammation in Irritable Bowel Syndrome: Sex- and Gender-Related Disparities—Quantity, Quality, or Both?. <i>American Journal of Gastroenterology</i> , 2009, 104, 401-403.	0.2	5
38	Impaired intestinal molecular tightness in the mucosa of irritable bowel syndrome: what are the mediators?. <i>Gut</i> , 2009, 58, 161-162.	6.1	4
39	Metabotyping of Biofluids Reveals Stress-Based Differences in Gut Permeability in Healthy Individuals. <i>Journal of Proteome Research</i> , 2009, 8, 4799-4809.	1.8	33
40	Toll-Like Receptor 4-Mediated Regulation of Spontaneous Helicobacter-Dependent Colitis in IL-10-Deficient Mice. <i>Gastroenterology</i> , 2009, 137, 1380-1390.e3.	0.6	61
41	Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. <i>Psychoneuroendocrinology</i> , 2008, 33, 1248-1256.	1.3	61
42	Maladaptive Intestinal Epithelial Responses to Life Stress May Predispose Healthy Women to Gut Mucosal Inflammation. <i>Gastroenterology</i> , 2008, 135, 163-172.e1.	0.6	112
43	Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. <i>Current Molecular Medicine</i> , 2008, 8, 258-273.	0.6	28
44	GEF-H1 Mediated Control of NOD1 Dependent NF- κ B Activation by Shigella Effectors. <i>PLoS Pathogens</i> , 2008, 4, e1000228.	2.1	99
45	Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. <i>Gut</i> , 2007, 56, 203-209.	6.1	330
46	Targeting mast cells in the treatment of functional gastrointestinal disorders. <i>Current Opinion in Pharmacology</i> , 2006, 6, 541-546.	1.7	50
47	Anisakis Simplex-Induced Small Bowel Obstruction After Fish Ingestion: Preliminary Evidence for Response to Parenteral Corticosteroids. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 667-671.	2.4	23
48	Pathogenesis of irritable bowel syndrome: The mast cell connection. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 129-140.	0.6	74